ANTI-ABETA VACCINE THERAPY
    5.
    发明申请

    公开(公告)号:US20220226447A1

    公开(公告)日:2022-07-21

    申请号:US17612921

    申请日:2020-05-20

    申请人: AC Immune SA

    IPC分类号: A61K39/00 A61K39/39 A61P25/28

    摘要: A liposomal vaccine composition comprising: a. A β-amyloid (Aβ)-derived peptide antigen displayed on the surface of the liposome that comprises, consists essentially of or consists of amino acids 1-15 of Aβ, b. An adjuvant comprising monophosphoryl lipid A (MPLA) is used for inducing an anti-Aβ immune response in a human subject without inducing a serious adverse event. The β-amyloid (Aβ)-derived peptide antigen (SEQ ID NO: 1) is administered in an amount of 300-2000 μg, preferably around 1000 μg. The MPLA is administered in an amount of 15-600 μg, preferably around 175 μg. The liposomal vaccine composition is administered intramuscularly or subcutaneously.